Journal of Cancer Therapeutics and Research ( ISSN: 2049-7962 ) is an open access journal published by Herbert publications ltd.
Journal of Cancer Therapeutics and Research is an online peer-reviewed journal following the guidelines provided by ICMJE and COPE. The journal has achieved all its success by the constant support and guidance of the Editor-in-Chief, Senior Editors and the Editorial board, consisting of about 80 eminent persons in the field.
The journal has published 55 articles in 2012 and 2013. Articles majorly published in subject areas “Cancer Therapy” and “Clinical Cancer Research”.
Articles published in
Aims and scope | Open access | Criteria for Publication | Benefits of publishing in Journal of Cancer Therapeutics and Research | Article Processing Charges | Submission of Manuscript | Publication Ethics | Editorial policies | Peer-Review Policy | Plagiarism Check | Manuscript Transfer Agreement | Contact
This page includes information about the aims and scope of Journal of Cancer Therapeutics and Research, editorial policies, the peer-review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Journal of Cancer Therapeutics and Research is an Open Access Publication which aims to publish quality papers on Epidemiology, Genetics and Genomics, Molecular Diagnostics, Translational Therapeutics, Clinical Studies of Cancer Research.
Scope of the Journal involves Molecular Pathobiology, cellular pathobiology, tumor and stem cell biology, metastasis, tumor suppressor, microenvironment and immunology, prevention and epidemiology, integrated systems and technology, therapeutics and targets.
Tumor and Stem Cell Biology
Prognostic Factors and Radiation Biology
Cancer Stem Cell Pathway
Cell Cycle and Checkpoints
DNA Repair and Apoptosis
Nuclear Serine-Threonine Kinases
Signal Transduction and Ubiquitin-related Pathway
|Cancer Therapy (Preclinical and clinical)
Central Nervous System Tumors
Head and Neck Cancer
Cancer Prevention & Epidemiology
The Herbert Open Access Journals (HOAJ) adopts the Creative Commons Attribution License toall works published (read the human-readable summary or the full license legal code) providing immediate and permanent access for free to all types of original works. The license grants copyrights to the author concerned and make the articles available for their dissemination. Anyone can use the articles in any constructive way as long as the credit is given to the author and citation to the original source.
No permission is required from the authors or the publishers.
In most cases, appropriate attribution can be provided by simply citing the original article. If any item the author plans to reuse is not part of the submitted manuscript, the origin of the work has to be cited correctly with the volume, issue, and date of the journal in which the item appeared. The author also has to indicate license terms under which the original source was published.
This broad license facilitates reader free online access to all types of original works and grants permission to reuse, re-copy and reproduce the work. Under this license, the author is free to make their work available to open access and distribution without any permission from the publisher. Learn more about Open Access. For queries about the license, please contact us.
To be appropriate for Journal of Cancer Therapeutics and Research, articles need to be of outstanding quality, broad interest and special importance. Initial decisions are held by Editors-in-Chief and submitted manuscripts will undergo unbiased preliminary assessment for the suitability to the scope of the journals. This will be determined during peer review process and by the advice of a member of the editorial board or somebody of equivalent standing. There are no restrictions on the length of articles submitted, but authors are suggested to be concise in regard with the reader’s interest.
Although articles contain sound information, it should fall under the journal’s scope. Article will not be considered for publication even the importance is closely related. This will become apparent only after the peer review process. However, the authors may be offered publication in the most appropriate subject-specific HOAJ journals through Manuscript Transfer Policy.
Journal of Cancer Therapeutics and Research open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results. Herbert Publications promotes all the published articles and content through free email alerts. It also provides wide range publicity and increased visibility to the articles in journals via updating on social networking sites like Facebook, Twitter and Google plus.
Currently, Journal of Cancer Therapeutics & Research & its articles are associated with following sources: CAS, HINARI, Google Scholar, Index Copernicus, JournalTOCs, SHERPA RoMEO, Pubshub, J-Gate, Citefactor, Academic Keys, Electronics Journals Library, SciForum.
For details follow this link : http://www.hoajonline.com/jctr/indexing-archiving
Article Metrics Provide clear insights about Article views, Pdf downloads, citation of articles (Crossref Citation Tool), Social Media likes & Sharing(Facebook, Google Plus, Twitter), Comments on article, related articles in Google Scholor, Indexed sources like pubmed, europe pubmed e.t.c
To view example on how articles metrics are presented for each article, please follow the link:
Journal offers a fast publication schedule whilst maintaining rigorous peer review process. All articles must be submitted online, and peer review is managed fully electronically aimed to take the final decision within 6 weeks from the manuscript submission. The article will subsequently be published immediately in both fully browsable web form, and as a formatted PDF; the article will then be available through Journal of Cancer Therapeutics and Research.
Herbert publications encourage submitting all the research content and offer proper space to full text, supplements, tables, figures, color illustrations and additional information related to the submitted manuscript. It provides appropriate links to all the supplements and permanent access online.
Articles are published under the Creative Commons Attribution License, providing immediate and permanent access for free to all types of original works. The license grants copyrights to the author concerned and make the articles available for their reuse and dissemination.
Please Contact Us, for more information about the benefits of publishing in a journal from Herbert Publications.
Open Access publishing is not free of cost to the author. Herbert Publications is an independent organization and dedicated to provide immediate barrier free open access to all its research content permanently for any internet user in the world. Herbert Publications ask for an affordable Article Processing Charge from the author to cover its administration costs, publication process and maintenance.
For Journal of Cancer Therapeutics and Research the publication fee is US$800.
50% fee waiver on the journal's processing cost will be granted to the author from Low-middle income countries and Low-income economies. Click Here to find list of countries to which waiver will be provided.
Manuscripts must be submitted to Journal of Cancer Therapeutics and Research electronically using the online submission system. Depending on the article type, full details on how to prepare and submit a manuscript are given in the instructions for Authors.
Journal of Cancer Therapeutics and Research recognizes the effort and involvement of a scholar in publishing an academic research work. To display quality in its articles, Herbert Publications support COPE guidelines and uphold high standards of publication ethics to all of its journals. To ensure fair evaluation process, all the submitted manuscripts undergo single-blind peer review process. The process involves strict measures to prevent plagiarism, redundancy of manuscripts, fabrication of data and multiple submissions.
A declaration should be provided for any report on experiments involving human subjects substantiating that informed consent was obtained from the subject(s) and/or guardian(s). In the cover letter corresponding author should clearly state that the informed consent was obtained.
Editorial policies are subjected to protect and strengthen the journals integrity and quality aiming reader's interest. In accordance to WAME definitions, Herbert Publications provides complete editorial freedom to the Editors-in-Chief with authority to determine journal's content and does not interfere with any sort of evaluation process of manuscripts.
All the articles are produced with respect to the scope of the journal based on relevancy, integrity, scientific strength, potential interest, completeness, clarity and ethics. Decisions on manuscripts are not affected by the author's origin, nationality, ethnicity, race, religion or political beliefs. No government policies or agencies away from the journal will determine the decision. Decisions taken are strictly based on the articles validity and importance to the scientific readers. For more information visit Editorial Board Policy. Authors who publish in Journal of Cancer Therapeutics and Research retain copyright to their work.
Herbert Publications closely suggest authors to declare transparency in any case of duplication and demonstrate significant development in the submitted manuscript than the original article with correct citations. We endorse COPE and ICMJE guidelines to handle the submitted manuscript in case suspected for any duplication or substantial overlap. In compliance with the Helsinki Declaration, it is highly recommended to mention the ethical approvals for animal experimentation, sample collection or trials on humans with their consent. Also maintain transparency to acknowledge competing interest and disclose any partial benefits from individuals in manuscript preparation or funding resources for the research. It is also firmly suggested to declare that work is purely original and not submitted or published elsewhere.
Journal of Cancer Therapeutics and Research operate single blinded peer review system with rapid and thorough process through electronic submissions and communications. In this process the authors names and affiliations will be revealed to the reviewers, while authors are kept blinded from reviewer details. More information is available at Peer-Review Policy page.
With the interest of maintaining integrity and Publication Standards, the journal employs a plagiarism detection system to subject the manuscript for plagiarism check. By submitting your manuscript to this journal you agree to screen the manuscript prior to evaluation process for plagiarism check against formerly published works. If found in any case that the manuscript is infringed against publication policies, it can be either suspended or rejected at any stage of peer-review process. Hence the authors are closely suggested to declare transparency in any case of duplication and demonstrate significant development in the submitted manuscript than the original article with correct citations.
We check the plagiarism using CrossCheck powered by iThenticate,
an initiative started by CrossRef.
For more details, please follow the link:
Manuscript transfer agreement facilitates authors with a mutual transfer of the manuscript between Herbert Publications journals. With respect to the editorial independence, when an editor of a journal decides that the submitted manuscript is not suitable to the scope of that journal, manuscript can be transferred to a more suitable journal as suggested by the editor with author's consent. More information is available on Manuscript Transfer Policy page.